الفهرس | Only 14 pages are availabe for public view |
Abstract The novel coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, represents a public health emergency, causing a significant morbidity and mortality worldwide (1). It was first reported on 8 December 2019 in Hubei province ?? Wahan, China and designated as a pandemic by the World Health Organization (WHO) on 11 March 2020 (2). Whereas COVID-19 essentially affects the lungs causing interstitial pneumonitis and severe acute respiratory distress syndrome, it also affects other organs; especially the cardiovascular system (3). COVID-19 effect on the cardiovascular system could be divided into primary and secondary cardiac involvement; there is much overlap between them both, primary cardiac manifestations of COVID-19 disease include arrhythmias, acute coronary syndrome (ACS) and myocarditis, also secondary cardiac involvement is usually due to systemic inflammatory response as acute myocardial injury and CHF (4). The incidence of acute coronary syndrome increases in the setting of viral infection, likely due to inflammatory-mediated plaque destabilization, the risk in the setting of COVID-19 infection is unknown, but other viruses are associated with a 3 to 10 fold increased risk (5). Direct viral entry through the angiotensin-converting enzyme 2 (ACE2) receptor and toxicity in host cells, hypoxia-related myocyte injury and immune-mediated cytokine release syndrome represents the potential mechanism of cardiac injury (6). Use of cardiac computed tomography (CT) is one of the areas that has witnessed a sudden increase in use and value since the beginning of COVID-19 outbreak with a large reduction in elective diagnostic testing and face-to-face patient care. |